Evidence map›Paper›PMID 38014249›Full record

ArticlebioRxiv : the preprint server for biology2024

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides.

Malik Zohaib Ali, Taru S Dutt, Amy MacNeill, Amanda Walz, Camron Pearce, Ha Lam, Jamie Philp, Johnathan Patterson, Marcela Henao-Tamayo, Richard E Lee and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Malik Zohaib Ali
Taru S Dutt
Amy MacNeill
Amanda Walz
Camron Pearce
Ha Lam
Jamie Philp
Johnathan Patterson
Marcela Henao-Tamayo
Richard E Lee
Jiuyu Liu
Gregory T RobertsonORCID 0000-0001-7157-4034
Anthony J Hickey
Mercedes Gonzalez-JuarreroORCID 0000-0002-4045-2365
Colorado State University · USSt. Jude Children's Research Hospital · USRTI International · USUniversity of Tennessee Health Science Center · US

Funding

Development of Novel Proteins Synthesis Inhibitors for MDR TuberculosisR01AI090810 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LEE, RICHARD E. · 2010 to 2022
$8.9M
NIAID NIH HHS R01 AI090810
6 · The paper itself

Abstract

The Nix-TB clinical trial evaluated a new 6-month regimen containing three-oral- drugs; bedaquiline (B), pretomanid (Pa) and linezolid (L) (BPaL regimen) for treatment of tuberculosis (TB). This regimen achieved remarkable results as almost 90% of the multidrug resistant (MDR) or extensively drug resistant (XDR) TB participants were cured but many patients also developed severe adverse events (AEs). The AEs were associated with the long-term administration of the protein synthesis inhibitor linezolid. Spectinamide 1599 is also a protein synthesis inhibitor of IMPORTANCE: Tuberculosis (TB) is an airborne infectious disease that spreads via aerosols containing

Identifiers

PMID38014249
PMCPMC10680823
OpenAlexW4388774292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.